Page last updated: 2024-12-10

trovirdine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

trovirdine: HIV-1 reverse transcriptase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3000870
CHEMBL ID39999
SCHEMBL ID636095
MeSH IDM0251497

Synonyms (36)

Synonym
ly300046hcl
bdbm1866
ly-300046 hcl
3-(5-bromopyridin-2-yl)-1-[2-(pyridin-2-yl)ethyl]thiourea hydrochloride
n-(2-(2-pyridylethyl))-n -(2-(5-bromopyridyl))thiourea
trovirdine
1-(5-bromo-2-pyridyl)-3-[2-(2-pyridyl)ethyl]thiourea
thiourea, n-(5-bromo-2-pyridinyl)-n'-[2-(2-pyridinyl)ethyl]-
ly-300046 (hcl)
hi-142 ,
149488-17-5
CHEMBL39999
ly-300046
1-(5-bromopyridin-2-yl)-3-(2-pyridin-2-ylethyl)thiourea
trovirdine [inn]
ze3k6j8614 ,
1-(5-bromo-2-pyridyl)-3-(2-(2-pyridyl)ethyl)-2-thiourea
unii-ze3k6j8614
SCHEMBL636095
HY-15349
CS-5538
AKOS030526567
ly300046
trovirdinely300046
1-(5-bromopyridin-2-yl)-3-(2-(pyridin-2-yl)ethyl)thiourea
BCP20663
trovirdine (ly-300046)
A13199
N17007
Q27295380
MS-25108
troviridine
NCGC00522539-01
ZFA48817
n-(5-bromopyridin-2-yl)-n'-[2-(pyridin-2-yl)ethyl]thiourea
DTXSID00869977
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)0.74000.00060.91418.3200AID1795346; AID1795367
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)1.15460.00011.076810.0000AID197780; AID197795; AID197803; AID198228; AID198229; AID198231; AID198409; AID198410; AID198411; AID199242; AID199243; AID200150; AID386493; AID404605
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Ki0.60000.00031.552310.0000AID198770
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1EC50 (µMol)0.02000.00040.61539.7000AID106954
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Activity0.02000.00091.30738.0000AID199980
Reverse transcriptase/RNaseH Human immunodeficiency virus 1ED500.02000.00020.99359.8000AID105522
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC90 (µMol)12.00000.00170.03850.3100AID198576
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (78)

Assay IDTitleYearJournalArticle
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID233026Selective index was evaluated from inhibitory concentrations of compound1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID81595Inhibitory activity against NNI-resistant HIV-1 strain A17 with Y181C mutation2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID197795Inhibition of HIV-1 reverse transcriptase using rCdG as template and dGTP as substrate1995Journal of medicinal chemistry, Dec-08, Volume: 38, Issue:25
Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs.
AID397178Ratio of EC50 for HIV1 3B expressing reverse transcriptase Y181C mutant to EC50 for HIV1 3B2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID106582Concentration required to reduce the viability of mock-infected MT-4 cells by 50% was determined by MTT method2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.
AID155278Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain HTLV IIIB in peripheral blood mononuclear cells (PBMC)1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID152658Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain A17 variant; Not determined1999Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID386493Inhibition of HIV1 recombinant wild type reverse transcriptase2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Parallel synthesis, molecular modelling and structure-activity relationship studies on analogues of O-(2-phenylethyl)-N-phenylthiocarbamate.
AID81257Concentration required to reduce the amount of p24 by 90% in HIV-1 infected C8166 cultures2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.
AID228281Compound was evaluated for the cytotoxic activity by using Microculture Tetrazolium assay (MTA)1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID105566Antiviral activity was determined against HIV-1 (clone 118) in MT-4 cells infected with HIV-1 IIIB using an XTT assay1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID197780Compound was evaluated for its inhibitory activity against recombinant HIV-1 Reverse transcriptase using cell free RT inhibition assay2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID157558Cytotoxic concentration was evaluated using microculture tetrazolium assay (MTA)1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID198770Binding affinity against HIV reverse transcriptase (Estimated Ki)2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID199243Inhibitory effect on recombinant HIV- 1 reverse transcriptase which has a mutation Tyr 181 to Cys 181 (clone 90)1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID155276Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain A17 variant (Y181C,K103N) in peripheral blood mononuclear cells (PBMC)1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID105547Tested for the inhibition of wild type HIV-1 (IIIB) replication in MT-4 cells1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID155270Ability to inhibit the replication of A17 variant (Y181C,K103N) strain of HIV-1 p24 antigen production in PBMC1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID198409Tested for the inhibition of mutant type (Cys181) HIV-1 (IIIB) RT1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID397179Antiviral activity against HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID105571Antiviral activity was determined against wild type HIV-1 in MT-4 cells infected with HIV-1 IIIB using an XTT assay1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID155272Ability to inhibit the replication of HTLV IIIb strain of HIV-1 p24 antigen production in PBMC1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID198229Inhibition of recombinant reverse transcriptase (RT) in cell-free Quan-T-RT assay system1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID155133Ability to inhibit the replication of A17 (Y181C) strain of HIV-1 p24 antigen production in PBMC1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID386494Antiviral activity against HIV1 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Parallel synthesis, molecular modelling and structure-activity relationship studies on analogues of O-(2-phenylethyl)-N-phenylthiocarbamate.
AID374090Antiviral activity against HIV1 3B Y181C resistant mutant in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID155280Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain RT-MDR(V106A) in peripheral blood mononuclear cells (PBMC)1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID106954Concentration required to achieve 50% protection of MT-4 cell from the HIV-1 induced cytopathogenicity was determined by the MTT method2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.
AID200150Activity of selected HIV-1 N-acylthiocarbamates in enzyme assay against Virion-Associated reverse transcriptase2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.
AID155290Inhibit the replication of the HIV-1 strain HTLV111B in human peripheral blood mononuclear cell2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID386486Cytotoxicity against human MT4 cells by MTT assay2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Parallel synthesis, molecular modelling and structure-activity relationship studies on O-[2-(hetero)arylethyl]-N-phenylthiocarbamates.
AID374087Antiviral activity against wild type HIV1 3B in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID105522Concentration which reduced the cytopathic effect of HIV-1 in MT-4 infected cells1995Journal of medicinal chemistry, Dec-08, Volume: 38, Issue:25
Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs.
AID198231Inhibition of purified recombinant HIV-1 reverse transcriptase1999Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID404604Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 cells2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID79121Inhibitory activity against multidrug resistant HIV-1 strain RT-MDR2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID397173Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID152661Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain HTLV IIIB wild type.1999Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID155274Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain A17 (Y181C) in peripheral blood mononuclear cells (PBMC)1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID397174Cytotoxicity against human MT4 cells by MTT assay2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID152775Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain RT-MDR.1999Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID374086Cytotoxicity against mock-infected human MT4 cells by MTT assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID155460Inhibitory effect on p24 production in HIV-infected peripheral blood mononuclear cells.1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID198228Inhibitory activity against recombinant HIV-1 reverse transcriptase (rRT)1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID198576Inhibition of recombinant reverse transcriptase (RT) in cell-free Quan-T-RT assay system1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID386497Reduction of HIV1 p24 antigen level in virus infected C8166 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Parallel synthesis, molecular modelling and structure-activity relationship studies on analogues of O-(2-phenylethyl)-N-phenylthiocarbamate.
AID404605Inhibition of HIV1 virion-associated reverse transcriptase2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID404603Antiviral activity against HIV1 in MT4 cells assessed as reduction of virus induced cytopathogenicity by MTT method2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID386488Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV12008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Parallel synthesis, molecular modelling and structure-activity relationship studies on O-[2-(hetero)arylethyl]-N-phenylthiocarbamates.
AID310934Antiviral activity against HIV1 in MT4 cells assessed as reduction of virus-induced cytopathicity by XTT assay2007Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8
Predicting anti-HIV activity of PETT derivatives: CoMFA approach.
AID404602Cytotoxicity against human MT4 cells by MTT method2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID397177Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID105568Antiviral activity was determined against HIV-1 (clone 90) in MT-4 cells infected with HIV-1 IIIB using an XTT assay1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID386496Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV12008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Parallel synthesis, molecular modelling and structure-activity relationship studies on analogues of O-(2-phenylethyl)-N-phenylthiocarbamate.
AID248354Concentration required to inhibit 50% viral production of human immunodeficiency virus type 1 (HIV-1-IIIB)2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
AID155273Ability to inhibit the replication of RT-MDR (V106A) strain of HIV-1 p24 antigen production in PBMC1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID374088Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID155287Compound was evaluated for cellular proliferation (on viability of peripheral blood mononuclear cells) using microculture tetrazolium assay (MTA).1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID198411Tested for the inhibition of wild type HIV-1 (IIIB) RT1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID198410Tested for the inhibition of mutant type (Ile100) HIV-1 (IIIB) RT1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID81597Inhibitory activity against NNI-resistant HIV-1 strain A17 with Y181C,K103N mutation2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID81800Ability to inhibit the replication of the NNI-sensitive/AZT-sensitive HIV-1 strain HTLV IIIB1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID104824Selectivity index which is the ratio of CC50 and EC50 was determined2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.
AID104944Concentration which reduced the viability of the HIV-1 infected MT-4 cells to 50% compared to untreated control cells1995Journal of medicinal chemistry, Dec-08, Volume: 38, Issue:25
Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs.
AID105572Antiviral activity was determined against wild type HIV-1 in MT-4 cells infected with HIV-1 IIIB using an XTT assay1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID152660Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain A17; Not determined1999Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID199980Inhibitory activity against human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT)2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
AID386487Antiretroviral activity against HIV1 in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Parallel synthesis, molecular modelling and structure-activity relationship studies on O-[2-(hetero)arylethyl]-N-phenylthiocarbamates.
AID81087Anti HIV-1 activity of selected N-acylthiocarbamates against Y181C resistant mutant2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.
AID199242Inhibitory effect on recombinant HIV- 1 reverse transcriptase which has a mutation Leu 100 to Ile 100 (clone 118)1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID386495Cytotoxicity against mock-infected human MT4 cells by MTT assay2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Parallel synthesis, molecular modelling and structure-activity relationship studies on analogues of O-(2-phenylethyl)-N-phenylthiocarbamate.
AID386491Antiviral activity against HIV1 in human C8166 cells assessed as reduction of p24 antigen level2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Parallel synthesis, molecular modelling and structure-activity relationship studies on O-[2-(hetero)arylethyl]-N-phenylthiocarbamates.
AID397175Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID197803Inhibitory effect on wild type HIV- 1 reverse transcriptase using rCdG as template and dGTP as substrate.1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1795367HIV-1 RT Assay from Article 10.1021/jm950639r: \\Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.\\1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID1795346HIV-1 RT Assay from Article 10.1021/jm00025a010: \\Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs.\\1995Journal of medicinal chemistry, Dec-08, Volume: 38, Issue:25
Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (41.67)18.2507
2000's13 (54.17)29.6817
2010's0 (0.00)24.3611
2020's1 (4.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.26 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]